J 2023

The Impact of Subclinical Hypothyroidism on the Quality of Life During Pregnancy: Mapping 5-Level Version of EQ-5D and ThyPRO-39

TUZIL, Jan, Barbora FILKOVA PILNACKOVA, Torquil WATT, Jan JISKRA, Marcela KOUDELKOVÁ et. al.

Základní údaje

Originální název

The Impact of Subclinical Hypothyroidism on the Quality of Life During Pregnancy: Mapping 5-Level Version of EQ-5D and ThyPRO-39

Autoři

TUZIL, Jan (203 Česká republika, garant), Barbora FILKOVA PILNACKOVA (203 Česká republika), Torquil WATT, Jan JISKRA (203 Česká republika), Marcela KOUDELKOVÁ (203 Česká republika, domácí), Eva NOVOTNA (203 Česká republika), Klara TUZILOVA (203 Česká republika), Tomáš DOLEŽAL (203 Česká republika, domácí) a Jana BARTAKOVA (203 Česká republika)

Vydání

Value in health, NEW YORK, ELSEVIER SCIENCE INC, 2023, 1098-3015

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 4.500 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133293

Organizační jednotka

Lékařská fakulta

UT WoS

001029792800001

Klíčová slova anglicky

EQ-5D; hypothyroidism; pregnancy; quality of life; ThyPRO-39

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 29. 1. 2024 12:57, Mgr. Tereza Miškechová

Anotace

V originále

Objectives: To describe how subclinical hypothyroidism (SubHypo) influences the quality of life (QoL) during pregnancy. Methods: In primary data collection (NCT04167423), thyroid stimulating hormone (TSH), free thyroxine (FT4), thyroid peroxidase antibodies, generic quality of life (QoL; 5-level version of EQ-5D [EQ-5D-5L]), and disease-specific QoL (ThyPRO-39) were measured among pregnant women. SubHypo during each trimester was defined according to the 2014 European Thyroid Association guidelines (TSH . 2.5, 3.0, and 3.5 IU/L, respectively; with normal FT4). Path analysis described relationships and tested mediation. Linear ordinary least squares, beta, tobit, and two-part regressions were used to map ThyPRO-39 and EQ-5D-5L. Alternative SubHypo definition was tested in sensitivity analysis. Results: A total of 253 women at 14 sites (31 & PLUSMN; 5 years old, 15 & PLUSMN; 6 weeks pregnant) completed the questionnaires. Sixty-one (26%) had SubHypo and differed from 174 (74%) euthyroid women in smoking history (61% vs 41%), primiparity (62% vs 43%) and TSH level (4.1 & PLUSMN; 1.4 vs 1.5 & PLUSMN; 0.7 mIU/L, P < .001). EQ-5D-5L utility in SubHypo (0.89 & PLUSMN; 0.12) was lower than that in euthyroid (0.92 & PLUSMN; 0.11; P = .028) even after adjustment (difference 20.04, P = .033), whereas ocular (P = .001, ThyPRO-39), cognitive symptoms (P = .043), anxiety (P < .0001), and the composite score were higher. The impact of SubHypo on utility was mediated by anxiety. Results were confirmed by sensitivity analysis. Final mapping equation (ordinary least squares) includes goiter symptoms, anxiety, upset stomach, composite score (ThyPRO-39), FT4 levels, and week of pregnancy (determination coefficient 0.36). Conclusion: This is the first QoL mapping of SubHypo during pregnancy and the first evidence that SubHypo is associated with a negative impact on QoL. The effect is mediated by anxiety. EQ-5D-5L utilities can be generated based on ThyPRO-39 scores collected in pregnant euthyroid and patients with SubHypo.